Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-09-12
1999-03-30
Feisee, Lila
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 8, 514 17, 514 18, 514 9, 530300, 530317, 530322, 530329, 530330, C07K 706, C07K 512, C07K 510, A61K 3804
Patent
active
058889787
ABSTRACT:
The present invention provides methods for reducing the severity of GI damage in an individual by administering a cytokine regulatory agent to an individual that is susceptible to developing such damage.
REFERENCES:
patent: 5420109 (1995-05-01), Suto et al.
Webster's II New Riverside University Dictionary, Riverside Publishing Co.:USA, p. 828, 1994.
Casini-Raggi et al., Anti-inflammatory effects of CGP 47969A, a novel inhibitor of proinflammatory cytokine synthesis, in rabbit immune colitis, Gastroenterology, 109: 821-818, Sep. 1995.
Radford-Smith et al., The role of cytokines in inflammatory bowl disease, Mediators of Inflammation, 3: 3-9, 1994.
Abou-Mohamed et al., "HP-228, a novel synthetic poeptide, inhibits the induction of nitric oxide synthase in vivo but no in vitro." J. Pharmacol. Exp. Ther., 275(2):584-591 (Nov. 1995).
Perkins et al.,"Polymer delivery of the active isomer of misoprostol: a solution to the intestinal side effect problem." J. of Pharm. and Experimental Therapeutics, 269(1):151-156 (1994).
Perkins et al., "SC-46275: A potent, long-acting gastric antisecretory prostaglandin with low oral bioavailability in the dog." J. of Pharm. and Experimental Therapeutics, 259(3):1004-1007 (1991).
Sun et al., "Effects of a polysaccharide fraction from the roots of bupleurum falcatum L. on experimental gastric ulcer models in rats and mice." J. Pharm. Pharmacol., 43:699-704 (1991).
McCafferty et al., "Indomethacin-induces gastric injury and leukocyte adherence in arthritic versus healthy rats." Gastroenterology, 109:1173-1180 (1995).
Andrews et al., "Effect of nonsteroidal anti-inflammatory drugs on LFA-1 and ICAM-1 expression in gastric mucosa." Am. J. Physiol., 266 (4 Pt 1):G657-64 (1994).
Santucci et al., "Role of tumor necrosis factor .alpha. release and leukocyte margination in indomethacin-induced gastric injury in rats." Gastroenterology, 108:393-401 (1995).
Abstract of Wallace et al., "Nitric oxide-releasing non-steroidal anti-inflammatory drugs: a novel approach for reducing gastrointenstinal toxicity." J. Gastorenterol Hepatol., 9(Suppl) 1:S40-4 (1994).
Girten Beverly E.
Omholt Paul
Tuttle Ronald R.
Feisee Lila
Kaufman Claire M.
Trega Biosciences, Inc.
LandOfFree
Method for reducing the severity of gastro-intestinal damage does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for reducing the severity of gastro-intestinal damage, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for reducing the severity of gastro-intestinal damage will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1215109